[go: up one dir, main page]

HRP20050351A2 - Proline derivatives having affinity for the calcium channel alpha-2-delta subunit - Google Patents

Proline derivatives having affinity for the calcium channel alpha-2-delta subunit Download PDF

Info

Publication number
HRP20050351A2
HRP20050351A2 HR20050351A HRP20050351A HRP20050351A2 HR P20050351 A2 HRP20050351 A2 HR P20050351A2 HR 20050351 A HR20050351 A HR 20050351A HR P20050351 A HRP20050351 A HR P20050351A HR P20050351 A2 HRP20050351 A2 HR P20050351A2
Authority
HR
Croatia
Prior art keywords
pyrrolidine
carboxylic acid
formula
alkyl
compound
Prior art date
Application number
HR20050351A
Other languages
English (en)
Croatian (hr)
Inventor
James Rawson David
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HRP20050351A2 publication Critical patent/HRP20050351A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20050351A 2002-10-31 2003-10-22 Proline derivatives having affinity for the calcium channel alpha-2-delta subunit HRP20050351A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0225379.7A GB0225379D0 (en) 2002-10-31 2002-10-31 Therapeutic proline derivatives
PCT/IB2003/004697 WO2004039367A1 (fr) 2002-10-31 2003-10-22 Derives de proline presentant une affinite pour la sous-unite alpha-2-delta du canal de calcium

Publications (1)

Publication Number Publication Date
HRP20050351A2 true HRP20050351A2 (en) 2005-10-31

Family

ID=9946940

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050351A HRP20050351A2 (en) 2002-10-31 2003-10-22 Proline derivatives having affinity for the calcium channel alpha-2-delta subunit

Country Status (38)

Country Link
EP (1) EP1558246B1 (fr)
JP (2) JP3940416B2 (fr)
KR (2) KR20070046213A (fr)
CN (1) CN100418525C (fr)
AP (1) AP2005003295A0 (fr)
AR (1) AR041865A1 (fr)
AT (1) ATE468116T1 (fr)
AU (1) AU2003269411B2 (fr)
BR (1) BR0315839A (fr)
CA (1) CA2499698C (fr)
CO (1) CO5550430A2 (fr)
CR (1) CR7802A (fr)
DE (1) DE60332646D1 (fr)
DK (1) DK1558246T3 (fr)
EA (1) EA009767B1 (fr)
EC (1) ECSP055769A (fr)
ES (1) ES2343624T3 (fr)
GB (1) GB0225379D0 (fr)
GE (1) GEP20074127B (fr)
GT (1) GT200300234A (fr)
HR (1) HRP20050351A2 (fr)
IL (4) IL167799A (fr)
IS (1) IS7754A (fr)
MA (1) MA27481A1 (fr)
MX (1) MXPA05004662A (fr)
NL (1) NL1024677C2 (fr)
NO (1) NO330496B1 (fr)
OA (1) OA12954A (fr)
PA (1) PA8587201A1 (fr)
PE (1) PE20040553A1 (fr)
PL (1) PL376703A1 (fr)
RS (1) RS20050333A (fr)
TN (1) TNSN05122A1 (fr)
TW (2) TW200416030A (fr)
UA (1) UA81437C2 (fr)
UY (1) UY28043A1 (fr)
WO (1) WO2004039367A1 (fr)
ZA (1) ZA200502305B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0225379D0 (en) * 2002-10-31 2002-12-11 Pfizer Ltd Therapeutic proline derivatives
US20050043345A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
WO2005097741A1 (fr) * 2004-04-05 2005-10-20 Pfizer Limited Procédé de recristallisation de dérivés de la proline
WO2006092692A1 (fr) * 2005-03-01 2006-09-08 Pfizer Limited Utilisation d'associations d’inhibiteurs de pde7 et de ligands alpha-2-delta pour le traitement de la douleur neuropathique
WO2007142028A1 (fr) 2006-06-06 2007-12-13 Gifu University Analogue de pyrrolidine pour la prévention de la douleur neurogène et sa méthode de production
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie
KR20160024875A (ko) 2013-06-26 2016-03-07 제지앙 지우조우 파마슈티칼 컴퍼니 리미티드 피롤리딘-2-카르복실산 유도체를 위한 제조 방법
WO2015003723A1 (fr) * 2013-07-12 2015-01-15 Københavns Universitet Dérivés substitués de 4-proline en tant qu'antagonistes iglur
CN104418785A (zh) * 2013-09-05 2015-03-18 浙江九洲药业股份有限公司 一种药物中间体的制备方法
CN104829513B (zh) * 2014-02-11 2019-02-19 浙江九洲药业股份有限公司 一种2-羧基-4-甲氧基甲基吡咯烷衍生物的制备方法
CN104844495A (zh) * 2015-06-05 2015-08-19 武汉理工大学 一种(2s,4s)-4-苯硫基-l-脯氨酸盐酸盐的合成方法
WO2020120606A1 (fr) * 2018-12-12 2020-06-18 Esteve Pharmaceuticals, S.A. Nouveaux dérivés d'acide pyrrolidine-2-carboxylique pour le traitement de la douleur et d'états pathologiques associés à la douleur
TW202026281A (zh) * 2018-12-12 2020-07-16 西班牙商艾斯提夫製藥股份有限公司 用於治療疼痛和疼痛相關病症之新吡咯啶–2– 甲酸衍生物
EP3904339A1 (fr) * 2020-04-28 2021-11-03 Esteve Pharmaceuticals, S.A. Dérivés d'alkylaminoproline en tant que bloqueurs alfa-2-delta-1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1144930A (fr) * 1978-08-11 1983-04-19 Miguel A. Ondetti Derives mercaptoacyles de prolines substituees
US4316906A (en) 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
US4311705A (en) * 1980-10-06 1982-01-19 E. R. Squibb & Sons, Inc. Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines
ZA817601B (en) * 1980-11-24 1982-10-27 Squibb & Sons Inc Carboxyalkyl amino acid derivatives of various substituted prolines
CA2106762C (fr) * 1991-04-19 2000-10-10 Donald J. Kyle Peptides antagonistes de la bradykinine
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
WO1998005780A2 (fr) * 1996-08-02 1998-02-12 Neurex Corporation Antagonistes des canaux calciques actives par tension et procedes associes
JP3196106B2 (ja) * 1997-03-27 2001-08-06 参天製薬株式会社 ロイコトリエンａ４ヒドロラーゼ阻害剤
NZ506793A (en) * 1998-05-26 2003-03-28 Warner Lambert Co Conformationally constrained amino acid compounds and their use for treating epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain and neuropathological disorders
CO5300399A1 (es) * 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
GB0225379D0 (en) * 2002-10-31 2002-12-11 Pfizer Ltd Therapeutic proline derivatives

Also Published As

Publication number Publication date
KR20070046213A (ko) 2007-05-02
CO5550430A2 (es) 2005-08-31
GEP20074127B (en) 2007-06-11
AP2005003295A0 (en) 2005-06-30
CR7802A (es) 2007-10-23
HK1081441A1 (zh) 2006-05-19
GB0225379D0 (en) 2002-12-11
UY28043A1 (es) 2004-05-31
EA009767B1 (ru) 2008-04-28
EP1558246B1 (fr) 2010-05-19
JP4555263B2 (ja) 2010-09-29
RS20050333A (en) 2007-06-04
KR20050065646A (ko) 2005-06-29
NL1024677C2 (nl) 2005-07-04
EP1558246A1 (fr) 2005-08-03
IS7754A (is) 2005-03-17
MXPA05004662A (es) 2005-06-08
CN100418525C (zh) 2008-09-17
MA27481A1 (fr) 2005-08-01
CN1711081A (zh) 2005-12-21
JP2006516115A (ja) 2006-06-22
JP3940416B2 (ja) 2007-07-04
AR041865A1 (es) 2005-06-01
UA81437C2 (en) 2008-01-10
ZA200502305B (en) 2006-11-29
PE20040553A1 (es) 2004-08-28
ATE468116T1 (de) 2010-06-15
NO20051407L (no) 2005-07-26
DK1558246T3 (da) 2010-08-09
KR100750782B1 (ko) 2007-08-20
TW200633699A (en) 2006-10-01
PA8587201A1 (es) 2004-05-26
TNSN05122A1 (fr) 2007-05-14
GT200300234A (es) 2004-06-23
JP2006328078A (ja) 2006-12-07
OA12954A (en) 2006-10-13
CA2499698C (fr) 2009-01-20
BR0315839A (pt) 2005-09-27
IL201967A (en) 2011-06-30
PL376703A1 (pl) 2006-01-09
IL201966A (en) 2011-06-30
NO20051407D0 (no) 2005-03-17
CA2499698A1 (fr) 2004-05-13
ECSP055769A (es) 2005-08-11
NO330496B1 (no) 2011-05-02
IL167799A (en) 2011-03-31
WO2004039367A1 (fr) 2004-05-13
NL1024677A1 (nl) 2004-05-06
ES2343624T3 (es) 2010-08-05
AU2003269411B2 (en) 2009-06-18
EA200500581A1 (ru) 2005-12-29
TW200416030A (en) 2004-09-01
DE60332646D1 (de) 2010-07-01
IL201965A (en) 2011-03-31
AU2003269411A1 (en) 2004-05-25

Similar Documents

Publication Publication Date Title
JP4555263B2 (ja) カルシウムチャンネルα２δサブユニットに親和性を有するプロリン誘導体
EP1492761B1 (fr) Acides amines a affinite vis-a-vis de la proteine alpha-2-delta
CN101166524B (zh) 氨基酸衍生物
US7053122B2 (en) Therapeutic use of aryl amino acid derivatives
US7659305B2 (en) Therapeutic proline derivatives
US20040092498A1 (en) Substituted glycine derivatives for use as medicaments
EP1539687A1 (fr) Derives de glycine substitues servant de medicaments
HK1081441B (en) Proline derivatives having affinity for the calcium channel alpha-2-delta subunit
EP1528919A2 (fr) Utilisation therapeutique de derives d'acide amine d'aryle
HK1116417B (en) Amino acid derivatives

Legal Events

Date Code Title Description
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
A1OB Publication of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20081013

Year of fee payment: 6

OBST Application withdrawn